Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus PROCHLORPERAZINE EDISYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus PROCHLORPERAZINE EDISYLATE.
FLUPHENAZINE DECANOATE vs PROCHLORPERAZINE EDISYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic. It exerts its effects by blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway, and also has antagonistic activity at alpha-1 adrenergic, muscarinic, and histamine H1 receptors, contributing to its side effect profile.
Prochlorperazine is a phenothiazine antipsychotic that antagonizes dopamine D2 receptors in the brain, particularly in the chemoreceptor trigger zone, exerting antiemetic effects. It also blocks alpha-adrenergic and muscarinic receptors.
12.5-25 mg deep IM injection every 2-4 weeks, not exceeding 100 mg per dose.
Antiemetic: 5-10 mg IM/IV every 3-4 hours as needed, maximum 40 mg/day; or 25 mg PR twice daily. Antipsychotic: 10-20 mg IM/IV every 1-4 hours, maximum 40 mg/day; oral: 5-10 mg 3-4 times daily, maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 7-21 days) following IM injection, reflecting slow release from depot and prolonged redistribution.
Terminal elimination half-life is approximately 6-8 hours, but may be prolonged to 10-12 hours in elderly patients or those with hepatic impairment. In overdoses, half-life can extend beyond 24 hours.
Primarily renal (metabolites) and fecal (biliary). Estimated 50% renal, 50% fecal as metabolites.
Primarily renal excretion of metabolites (approximately 70-80% as conjugated metabolites), with less than 1% excreted unchanged. Fecal excretion accounts for about 20-30% via biliary elimination.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic